Cresco Labs

Cresco Labs carries a Neutral rating, with a composite score of 53 out of 100 and a conviction reading of 1 of 5. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the fundamentals pillar at 68, and pulls the composite into the middle of the band. Editorial lags at 30, softening what would otherwise be a stronger reading.

The scoring inputs are concrete: reported revenue growth of -8.7 percent year over year, an operating margin of 7.4 percent. Together they explain most of the pillar mix. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Cresco Labs can be compared against the global cannabis coverage universe on identical inputs, refreshed on the ingest cycle.

The clearest catalyst is the next quarterly print. Fundamentals contribute 68 of the composite, and either an acceleration in top-line growth or a stabilization of the operating margin would move the score higher; a deterioration on either would compress it.